The globally active CHEPLAPHARM Group, headquartered in Greifswald, has entered into a strategic partnership with South Korean pharmaceutical company Boryung for the manufacture of Zyprexa® tablets. Boryung is the second contract manufacturer with which CHEPLAPHARM is collaborating on the production of Zyprexa® tablets. CHEPLAPHARM is thus pursuing a dual sourcing strategy for Zyprexa® tablets in order to ensure improved product availability in the future.
CHEPLAPHARM acquired the global marketing rights (except South Korea) for Zyprexa® from Eli Lilly and Company in 2023. Boryung has held the rights for Zyprexa® in South Korea since 2021. Effective immediately, the South Korean company will support CHEPLAPHARM in manufacturing Zyprexa® tablets for up to 46 countries, including Europe and North America.
Boryung's Yesan Campus features state-of-the-art equipment capable of producing high-quality oral medications and is characterised by high production stability and capacity which was the deciding factor to collaborate with the South Korean company. The first deliveries of Zyprexa® tablets from Boryung are expected in 2026.
Artem Gevorkyan, SVP Corporate Development at CHEPLAPHARM, commented, "This successful CDMO agreement signing is a true testament to the brilliant collaboration and unwavering commitment of both CHEPLAPHARM and Boryung teams. Their joint efforts have established a robust foundation for the reliable supply of this high-quality, essential medicine to our patients globally. We are immensely proud of this critical milestone, which underscores our shared dedication to delivering meaningful impact through excellence and strong partnership.”
“Holding the marketing rights for Zyprexa® in South Korea and having established the production of the portfolio on their premises already, Boryung was our first point of contact for another manufacturer of Zyprexa® tablets. We are delighted to further expand our successful partnership with Boryung,” says Edeltraud Lafer, Co-CEO of CHEPLAPHARM. “The agreement will supplement our existing supply chain for our key product Zyprexa® tablets and is in line with our strategy to increase the resilience of our supply chain via dual sourcing and will improve ‘on time in full’ delivery. This partnership will help us service the global market for Zyprexa® tablets even better and ensure product availability for patients and prescribers.”
